Patent · US Expired

BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells

US6277972A · kind A · utility

11Cited by
0References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 10, 1999
Grant dateAug 21, 2001
Priority date
Expiry dateAug 10, 2019

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2799/027
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described is a novel gene and its encoded secreted tumor antigen, termed BPC-1, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express BPC-1, particularly including prostate cancer and bladder cancer. In human normal tissues, BPC-1 is only expressed in certain tissues of the brain. However, BPC-1 is expressed at high levels in prostate cancer cells and is also expressed in bladder cancer cells. The structure of BPC-1 includes a signal sequence and a CUB domain. BPC-1 protein is secreted. Preliminary experimental evidence suggests that BPC-1 is directly involved in oncogenesis or maintenance of the transformed phenotype of cancer cells expressing BPC-1. BPC-1 also appears to bind specifically to a cellular protein expressed in prostate cancer cells and other cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.